Recurrence of intracranial tumors following adoptive T cell therapy can be prevented by direct and indirect killing aided by high levels of tumor antigen cross-presented on stromal cells

Journal of Immunology

Volumn 183, Issue 3, 2009, Pages 1828-1837

  Thomas, Diana L ^a   Kim, Miri ^a   Bowerman, Natalie A ^a   Narayanan, Samanthi ^a   Kranz, David M ^a   Schreiber, Hans ^b   Roy, Edward J ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; H2 ANTIGEN; PEPTIDE ANTIBODY; RAG1 PROTEIN; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CD8+ T LYMPHOCYTE; CELL KILLING; CONTROLLED STUDY; CROSS PRESENTATION; IN VITRO STUDY; INTRACRANIAL TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; STROMA CELL; T LYMPHOCYTE; ADOPTIVE TRANSFER; ANIMAL; BRAIN TUMOR; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; IMMUNOLOGY; METHODOLOGY; MOUSE MUTANT; PATHOLOGY; RECURRENT DISEASE; TRANSPLANTATION; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CELL LINE, TUMOR; CROSS-PRIMING; CYTOTOXICITY, IMMUNOLOGIC; MICE; MICE, KNOCKOUT; RECURRENCE; STROMAL CELLS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 68149164402     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0802322     Document Type: Article

References (62)

1. June, C. H. 2007. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 117: 1466-1476.
2. Rosenberg, S. A., N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley. 2008. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8: 299-308.
3. Disis, M. L., H. Bernhard, and E. M. Jaffee. 2009. Use of tumour-responsive T cells as cancer treatment. Lancet 373: 673-683.
4. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
5. Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, et al. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23: 2346-2357.
6. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99: 16168-16173.
7. + T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 24: 5060-5069.
8. Holladay, F. P., T. Heitz, and G. W. Wood. 1992. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic lymphocytes-T, but not by lymphokine-activated killer cells. J. Neurosurg. 77: 757-762.
9. Kruse, C. A., K. O. Lillehei, D. H. Mitchell, B. Kleinschmidt-DeMasters, and D. Bellgrau. 1990. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take. Proc. Natl. Acad. Sci. USA 87: 9577-9581.
10. Merchant, R. E., N. G. Baldwin, C. D. Rice, and H. D. Bear. 1997. Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes. Neurol. Res. 19: 145-152.
11. Patrick, T. A., D. M. Kranz, J. F. Zachary, and E. J. Roy. 1998. Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors. Int. J. Cancer 78: 470-479.
12. Plautz, G. E., J. E. Touhalisky, and S. Y. Shu. 1997. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. Cell. Immunol. 178: 101-107.
13. Romani, L., M. C. Fioretti, R. Bianchi, B. Nardelli, and E. Bonmassar. 1982. Intracerebral adoptive immunotherapy of a murine lymphoma antigenically altered by drug treatment in vivo. J. Natl. Cancer Inst. 68: 817-822. (Pubitemid 12070938)
14. Schell, T. D., L. M. Mylin, I. Georgoff, A. K. Teresky, A. J. Levine, and S. S. Tevethia. 1999. Cytotoxic T lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice. J. Virol. 73: 5981-5993.
15. Yamasaki, T., and H. Kikuchi. 1989. An experimental approach to specific adoptive immunotherapy for malignant brain tumors. Nippon Geka Hokan 58: 485-492. (Pubitemid 20325089)
16. Holladay, F. P., T. HeitzTurner, W. L. Bayer, and G. W. Wood. 1996. Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with ggrade III/IV astrocytoma. J. Neurooncol. 27: 179-189.
17. Ingram, M., J. G. Buckwalter, D. B. Jacques, D. B. Freshwater, R. M. Abts, G. B. Techy, K. Miyagi, C. H. Shelden, R. W. Rand, and L. W. English. 1990. Immunotherapy for recurrent malignant glioma: an interim report on survival. Neurol. Res. 12: 265-273.
18. Kruse, C. A., L. Cepeda, B. Owens, S. D. Johnson, J. Stears, and K. O. Lillehei. 1997. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol. Immunother. 45: 77-87.
19. Plautz, G. E., G. H. Barnett, D. W. Miller, B. H. Cohen, R. A. Prayson, J. C. Krauss, M. Luciano, D. B. Kangisser, and S. Shu. 1998. Systemic T cell adoptive immunotherapy of malignant gliomas. J. Neurosurg. 89: 42-51.
20. Plautz, G. E., D. W. Miller, G. H. Barnett, G. H. Stevens, S. Maffett, J. Kim, P. A. Cohen, and S. Shu. 2000. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin. Cancer Res. 6: 2209-2218.
21. Sloan, A. E., R. Dansey, L. Zamorano, G. Barger, C. Hamm, F. Diaz, R. Baynes, and G. Wood. 2000. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg. Focus 9: e9.
22. Tsuboi, K., K. Saijo, E. Ishikawa, H. Tsurushima, S. Takano, Y. Morishita, and T. Ohno. 2003. Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clin. Cancer Res. 9: 3294-3302.
23. Tsurushima, H., S. Q. Liu, K. Tuboi, A. Matsumura, Y. Yoshii, T. Nose, K. Saijo, and T. Ohno. 1999. Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes. Jpn. J. Cancer Res. 90: 536-545.
24. Vaquero, J., R. Martinez, J. Ramiro, F. G. Salazar, L. Barbolla, and C. Regidor. 1991. Immunotherapy of glioblastoma with intratumoural administration of autologous lymphocytes and human lymphoblastoid interferon: a further clinical study. Acta Neurochir. 109: 42-45.
25. Kahlon, K. S., C. Brown, L. J. Cooper, A. Raubitschek, S. J. Forman, and M. C. Jensen. 2004. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 64: 9160-9166.
26. Wood, G. W., F. P. Holladay, T. Turner, Y. Y. Wang, and M. Chiga. 2000. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma. J. Neurooncol. 48: 113-120.
27. Fujita, M., X. Zhu, K. Sasaki, R. Ueda, K. L. Low, I. F. Pollack, and H. Okada. 2008. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J. Immunol. 180: 2089-2098.
28. Grauer, O. M., R. P. Sutmuller, W. van Maren, J. F. Jacobs, E. Bennink, L. W. Toonen, S. Nierkens, and G. J. Adema. 2008. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int. J. Cancer 122: 1794-1802.
29. Ahmed, N., M. Ratnayake, B. Savoldo, L. Perlaky, G. Dotti, W. S. Wels, M. B. Bhattacharjee, R. J. Gilbertson, H. D. Shine, H. L. Weiss, et al. 2007. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 67: 5957-5964.
30. Kjaergaard, J., L. Peng, P. A. Cohen, and S. Shu. 2003. Therapeutic efficacy of adoptive immunotherapy is predicated on in vivo antigen-specific proliferation of donor T cells. Clin. Immunol. 108: 8-20.
31. + T cells. J. Immunol. 179: 845-853.
32. Nishimura, F., J. E. Dusak, J. Eguchi, X. M. Zhu, A. Gambotto, W. J. Storkus, and H. Okada. 2006. Adoptive transfer of type 1 CTL mediates effective anticentral nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res. 66: 4478-4487.
33. Peng, L. M., J. Kjaergaard, G. E. Plautz, M. Awad, J. A. Drazba, S. Y. Shu, and P. A. Cohen. 2002. Tumor-induced L-selectin high suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. J. Immunol. 169: 4811-4821.
34. Wang, L. X., S. Shu, and G. E. Plautz. 2005. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells. Cancer Res. 65: 9547-9554.
35. + T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors. Cancer Immunol. Immunother. 57: 883-895.
36. Prins, R. M., C. J. Shu, C. G. Radu, D. D. Vo, H. Khan-Farooqi, H. Soto, M. Y. Yang, M. S. Lin, S. Shelly, O. N. Witte, et al. 2008. Antitumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol. Immunother. 57: 1279-1289.
37. Velicu, S., Y. Han, I. Ulasov, I. E. Brown, A. Andaloussi, T. F. Gajewski, and M. S. Lesniak. 2006. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy. J. Neuroimmunol. 174: 74-81.
38. Peres, E., G. W. Wood, J. Poulik, R. Baynes, S. Sood, M. H. Abidi, J. Klein, K. Bhambhani, R. Dansey, and E. Abella. 2008. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors. Neuropediatrics 39: 151-156.
39. Yamshchikov, G. V., D. W. Mullins, C. C. Chang, T. Ogino, L. Thompson, J. Presley, H. Galavotti, W. Aquila, D. Deacon, W. Ross, et al. 2005. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J. Immunol. 174: 6863-6871.
40. Kmieciak, M., K. L. Knutson, C. I. Dumur, and M. H. Manjili. 2007. HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated antitumor immune responses. Eur. J. Immunol. 37: 675-685.
41. Sampson, J. H., G. E. Archer, D. A. Mitchell, A. B. Heimberger, and D. D. Bigner. 2008. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin. Immunol. 20: 267-275.
42. Blankenstein, T. 2005. The role of tumor stroma in the interaction between tumor and immune system. Curr. Opin. Immunol. 17: 180-186.
43. Ibe, S., Z. Qin, T. Schuler, S. Preiss, and T. Blankenstein. 2001. Tumor rejection by disturbing tumor stroma cell interactions. J. Exp. Med. 194: 1549-1559.
44. Schuler, T., S. Kornig, and T. Blankenstein. 2003. Tumor rejection by modulation of tumor stromal fibroblasts. J. Exp. Med. 198: 1487-1493. (Pubitemid 37467163)
45. Spiotto, M. T., P. Yu, D. A. Rowley, M. I. Nishimura, S. C. Meredith, T. F. Gajewski, Y. X. Fu, and H. Schreiber. 2002. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via cross-presentation by bone marrow-derived stromal cells. Immunity 17: 737-747.
46. Zhang, B., N. A. Bowerman, J. K. Salama, H. Schmidt, M. T. Spiotto, A. Schietinger, P. Yu, Y. X. Fu, R. R. Weichselbaum, D. A. Rowley, et al. 2007. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204: 49-55.
47. Zhang, B., Y. Zhang, N. A. Bowerman, A. Schietinger, Y. X. Fu, D. M. Kranz, D. A. Rowley, and H. Schreiber. 2008. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res. 68: 1563-1571.
48. Jenny, B., J. A. Harrison, D. Baetens, J. C. Tille, K. Burkhardt, H. Mottaz, J. Z. Kiss, P. Y. Dietrich, N. De Tribolet, G. P. Pizzolato, and M. S. Pepper. 2006. Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas. J. Pathol. 209: 34-43.
49. Wesolowska, A., A. Kwiatkowska, L. Slomnicki, M. Dembinski, A. Master, M. Sliwa, K. Franciszkiewicz, S. Chouaib, and B. Kaminska. 2008. Microglia-derived TGF-β as an important regulator of glioblastoma invasion - an inhibition of TGF-β-dependent effects by shRNA against human TGF-β type II receptor. Oncogene 27: 918-930.
50. Aghi, M., K. S. Cohen, R. J. Klein, D. T. Scadden, and E. A. Chiocca. 2006. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res. 66: 9054-9064.
51. Singh, S., S. R. Ross, M. Acena, D. A. Rowley, and H. Schreiber. 1992. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175: 139-146.
52. Roggendorf, W., S. Strupp, and W. Paulus. 1996. Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol. 92: 288-293.
53. Morimura, T., C. Neuchrist, K. Kitz, H. Budka, O. Scheiner, D. Kraft, and H. Lassmann. 1990. Monocyte subpopulations in human gliomas: expression of Fc and complement receptors and correlation with tumor proliferation. Acta Neuropathol. 80: 287-294.
54. Graeber, M. B., B. W. Scheithauer, and G. W. Kreutzberg. 2002. Microglia in brain tumors. Glia 40: 252-259.
55. Badie, B., and J. M. Schartner. 2000. Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery 46: 957-961; discussion 961-952.
56. Thomas, D. L., D. M. Kranz, and E. J. Roy. 2008. Experimental manipulations of afferent immune responses influence efferent immune responses to brain tumors. Cancer Immunol. Immunother. 57: 1323-1333.
57. + glioma cells: possible targets of immunotherapy. J. Neurooncol. 83: 121-131.
58. Plautz, G. E., S. Mukai, P. A. Cohen, and S. Shu. 2000. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors. J. Immunol. 165: 3656-3662.
59. Calzascia, T., W. Di Berardino-Besson, R. Wilmotte, F. Masson, N. de Tribolet, P. Y. Dietrich, and P. R. Walker. 2003. Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain. J. Immunol. 171: 2187-2191. (Pubitemid 37025522)
60. Shanker, A., G. Verdeil, M. Buferne, E. M. Inderberg-Suso, D. Puthier, F. Joly, C. Nguyen, L. Leserman, N. Auphan-Anezin, and A. M. Schmitt-Verhulst. 2007. CD8 T cell help for innate antitumor immunity. J. Immunol. 179: 6651-6662.
61. + T cell tolerance. Eur. J. Immunol. 36: 2960-2970.
62. + T cells results in antigen-specific T cell tolerance. Nat. Med. 6: 1348-1354.